Formulation and optimization of Lacidipine (cas 103890-78-4) loaded niosomal gel for transdermal delivery: In-vitro characterization and in-vivo activity
-
Add time:07/25/2019 Source:sciencedirect.com
The aim of the present research work is to formulate Lacidipine (cas 103890-78-4) (LAC) loaded niosomes formulation for the management of hypertension by thin film hydration technique. The developed formulations were statistically optimized by four factors, three levels Box–Behnken design and were evaluated for vesicle size, entrapment efficiency, and flux. The optimized LAC niosomes was further evaluated for permeation depth by confocal laser scanning microscopy (CLSM) and converted to gel formulation. Further, the optimized LAC niosomes gel was evaluated for ex-vivo permeation study, skin irritation study, stability study and pharmacodynamics study. The optimized LAC niosomes formulation showed vesicle size, entrapment efficiency and flux value of 676.98 ± 10.92 nm, 82.77 ± 4.34% and 38.43 ± 2.43 μg/cm2/h respectively, with spherical morphology. The comparative CLSM study showed that optimized LAC niosomes formulation has shown maximum permeation (70.75 μm) as compare to LAC liposomes formulation (58.26 μm). The optimized LAC niosomes gel showed skin permeation enhancement of 2.15 times as compare to control gel. Furthermore, in vivo antihypertensive activity showed significantly higher (p < 0.001) reduction in blood pressure compared to oral suspension. Indeed, it was found that niosomal vesicles represented to be an efficient nano vesicular carrier for transdermal delivery of lacidipine.
We also recommend Trading Suppliers and Manufacturers of Lacidipine (cas 103890-78-4). Pls Click Website Link as below: cas 103890-78-4 suppliers
Prev:Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral Lacidipine (cas 103890-78-4) formulations in dogs
Next:Photodegradation studies on lacidipine in solution: basic experiments with a cis–trans reversible photoequilibrium under UV-A radiation exposure) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral Lacidipine (cas 103890-78-4) formulations in dogs07/24/2019
- Co-amorphous solid dispersion systems of Lacidipine (cas 103890-78-4)-spironolactone with improved dissolution rate and enhanced physical stability07/23/2019
- Rapidly dissolving Lacidipine (cas 103890-78-4) nanoparticle strips for transbuccal administration07/22/2019
- Lacidipine (cas 103890-78-4) attenuates TNF-α-induced cardiomyocyte apoptosis07/20/2019
- Synergetic effect of nucleation and crystal growth inhibitor on in vitro-in vivo performance of supersaturable Lacidipine (cas 103890-78-4) solid dispersion07/21/2019